<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Saniona..]]></title><description><![CDATA[<p dir="auto">Hej..jeg har et frimærke i danske Saniona, der er noteret på Aktietorvet i Stockholm - i de sidste par uger er den steget næsten 100 % - er der nogen der følger aktien og kan give en melding om jeg skal investere yderligere i aktien ?</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/439353/saniona</link><generator>RSS for Node</generator><lastBuildDate>Sat, 18 Jul 2026 14:50:14 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/439353.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 24 Mar 2016 07:28:43 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Saniona.. on Mon, 28 Mar 2016 05:48:14 GMT]]></title><description><![CDATA[<ol start="22">
<li>marts 2016 har selskabet udsendt en pressemeddelelse hvor essensen er følgende:</li>
</ol>
<p dir="auto">"Our vision for Tesomet is to develop a new type of treatment for diabetes, which can bring certain groups of patients in complete remission by contributing to a substantial weight loss through decreased food consumption," says Jørgen Drejer, CEO of Saniona."</p>
]]></description><link>https://dev.proinvestor.com/forum/post/9451607</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9451607</guid><dc:creator><![CDATA[ARM]]></dc:creator><pubDate>Mon, 28 Mar 2016 05:48:14 GMT</pubDate></item></channel></rss>